Should You Buy AbbVie Stock Before Oct. 30?
Key Points
AbbVie has generated solid double-digit growth in its most recent quarters.
Additional approvals for its top drugs could lead to more growth.
The stock's valuation is incredibly low based on its expected future profits.
- 10 stocks we like better than AbbVie ›
AbbVie (NYSE:ABBV) is a top healthcare company that's been doing well this year, rising by 17% in value, which is better than the S&P 500 and its gains of around 14%. It's been beating the market, and what could send its shares even higher is a strong earnings report for the third quarter.
In a few weeks, on Oct. 30, AbbVie will release its Q3 numbers. Here's why investors may want to consider buying the healthcare stock before then.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
The results are likely to be strong, again
In the past two quarters, AbbVie has generated strong growth, with its net revenue rising by more than 12% in the first quarter of 2026 and then by over 10% in the second quarter. The company's top-selling drugs, Rinvoq and Skyrizi, have also been obtaining more approvals from regulators, particularly in Europe, which could lead to stronger growth ahead.
The business has been doing extremely well, and yet there's still room for improvement in its oncology and aesthetics segments, which experienced modest declines in the second quarter.
With a broad and diverse business, AbbVie is in an excellent position to grow in both the short term and over the long run. Another period of double-digit growth could give investors an incentive to pile more money into this relatively safe healthcare stock, especially given how cheap it looks right now.
AbbVie's low valuation makes the stock a great buy right now
Acquisitions have bolstered AbbVie's business over the years, but one-time charges have also weighed down its financials in the process, which is why the stock may look expensive, with its price-to-earnings (P/E) multiple being a hefty 75. But based on its estimated future profits, its forward P/E multiple is just 16. By comparison, the average stock on the S&P 500 trades at close to 20 times its future profits.
And if its valuation wasn't enough of a reason to buy the stock, then the dividend could make AbbVie a no-brainer buy. At 2.6%, it’s a solid payout from a company that has an excellent track record of growing its dividend over the years.
For investors looking for a relatively safe stock to invest in, AbbVie is an attractive option for its modest valuation and excellent overall fundamentals. This is a stock that can be an excellent pillar to build a portfolio around and to simply hang on to for the long haul.
Should you buy stock in AbbVie right now?
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $364,023!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,467,933!*
Now, it’s worth noting Stock Advisor’s total average return is 948% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of October 6, 2026.
David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie. The Motley Fool has a disclosure policy.
Recommended Articles
